Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.
Nichi-Iko Pharmaceutical and Eisai are targeting China with the next phase of their collaboration, building on their existing partnership in Japan to take the next step of delivering Nichi-Iko’s generics to the Chinese market through Eisai’s marketing infrastructure.
“Under this agreement,” the firms announced, “Eisai and Nichi-Iko aim to enhance their pharmaceutical businesses in China by introducing high-quality...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
